Posted inGenetics
Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer Collaboration
Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s most advanced immuno-oncology asset, the prostate cancer candidate VIR-5500, through…







